Format

Send to

Choose Destination
Clin Lab. 2013;59(1-2):51-8.

Bortezomib modulates regulatory T cell subpopulations in the process of acute graft-versus-host disease.

Author information

1
Department of Haematology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou 510080, PR China.

Abstract

BACKGROUND:

Acute graft-versus-host disease (aGVHD) combines the wide application of allogeneic bone marrow transplantation (allo-BMT). Recent studies indicate that it is possible to reduce the incidence and severity of aGVHD by using bortezomib. In this study, we explored the changes of T cell subsets after allo-BMT with bortezomib, in order to elucidate the mechanism by which bortezomib attenuates aGVHD.

METHODS:

Following a single dose of lethal irradiation (TBI, 0.7 Gy/minutes, 8.0 Gy), BALB/c mice were injected with 2 x 10(7) C57BL/6 nucleated BM cells plus 1 x 10(7) splenocytes with or without bortezomib at 1.0 mg/kg. The ratio of CD4+CD25+ Foxp3+ regulatory T cells (Treg) was examined by flow cytometry, and the cytokine levels of IL-2 (Th1) and IL-4 (Th2) were detected by ELISA. Bivariate correlation analysis was carried out to evaluate changes of the Th1 and Th2 cytokines related to the changes of Treg.

RESULTS:

Bortezomib remarkably reduced aGVHD severity and prolonged the survival time. Along with bortezomib injection, the ratio of Treg was significantly increased and IL-2 level was decreased but IL-4 level was increased. Bivariate correlation analysis results evaluated the correlation between the increment of Treg and changes of Th1 and Th2 cytokines.

CONCLUSIONS:

Bortezomib may exert its effect by triggering the generation of Treg which might regulate the imbalance of Th1/Th2 during aGVHD.

PMID:
23505906
DOI:
10.7754/clin.lab.2012.120215
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center